Arrhythmias & electrophysiologyCohort study

Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States

Heart RhythmPublished

  • Retrospective analysis
  • propensity score matching

Authors' conclusion

CA treatment was associated with a lower risk of atrial tachyarrhythmia, cardioversion, HF hospitalization, and ischemic stroke than AADs. AADs were poorly tolerated in this cohort, and complication rates from CA were similar to those of younger groups. Favorable safety and efficacy support consideration of CA in elderly patients.

Study context

Population
Elderly patients (aged ≥65 years) with drug-refractory atrial fibrillation (AF), Optum Clinformatics database, 2016 to 2022patients identified · AAD cohort 7,230 · catheter ablation (CA) cohort 6,081
Participants
13,311 patients
Exposure
CA with AADs
  • CA cohortn = 6,081
  • AAD cohortn = 7,230reference
Outcome
Atrial tachyarrhythmia recurrence

Main finding

As reported in the abstract

Hazard ratio

0.76

95% CI 0.65–0.89

CA cohort vs AAD cohort
HR 0.76 (95% CI 0.65–0.89)

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
Direct current cardioversion · significantly reduced0.74 (0.60–0.91)
HF hospitalization · significantly reduced0.63 (0.45–0.90)
Ischemic stroke · significantly reduced0.45 (0.28–0.72)

Death or myocardial infarction

without differences in death or myocardial infarction

Safety

OutcomeCA cohortAAD cohort
Complications (CA) / adverse events (AAD)rate of complications 5.9%adverse events 45.4%

Original publication

Antiarrhythmic drugs vs catheter ablation for treatment of atrial fibrillation in an elderly population: A retrospective analysis of Medicare Advantage enrollees in the United States. Heart Rhythm. Published 6 March 2026. doi:10.1016/j.hrthm.2026.02.045

Summarised from the published abstract; every number is checked against it